Intellect Neurosciences Inc. (fka ILNS)

[montanus]

Ponezumab CAA trial result discussion September 8 2016

5th International CAA Conference 2016, Boston MA
September 8 @ 8:00 am - September 10 @ 12:00 pm

The 2016 Boston conference will bring together international leaders in laboratory- and patient-based research and clinical care in the rapidly growing and increasingly recognized field of cerebral amyloid angiopathy, one of the two major sporadic small vessel brain diseases.



Program:

September 8, 2016

8:40am – 10:00am Theme 1: Immunotherapy Trials in CAA and AD

Moderator: Anand Viswanathan

Reisa Sperling (8:40am – 9:10am) “AD Immunotherapy: Participants, Treatments and Imaging Markers”
Claire Leurent (9:10am – 9:30am) “CAA Immunotherapy: Results from the A9951024 Ponezumab Study”
Steven M. Greenberg (9:30am – 9:50am) “CAA Immunotherapy: Outcome Markers”
Fabrizio Piazza (9:50am – 10:10am) “Spontaneous Immunotherapy: Endogenous Autoantibodies to ß-Amyloid and the ARIA Paradox”
10:10am – 10:30am Break/Poster Viewing

10:30am – 12:15pm Theme 1 Cont: Immunotherapy Trials in CAA and AD

Oral Abstract, James Nicoll (10:30-10:45) “Neuropathology follow up of the first trial of Aß immunotherapy”
Panel Discussion of the Ponezumab study results (10:45am – 11:15am)
Oral Abstract Presentations (11:15am – 12:15pm)
12:15pm – 1:40pm Lunch break/Moderated Poster Presentations



September 8, 2016

1:40pm – 3:00pm Theme 2: Amyloid Clearance, Interstitial Fluid, and the Glymphatic Pathway

Moderator: Marcel Verbeek

Ben Plog (1:40pm – 2:20pm) “Novel Insight into Glymphatic Regulation”
Roxana Carare (2:20pm – 3:00pm) “Clearance Pathways for Interstitial and Cerebrospinal Fluid”
3:00pm – 3:20pm Break/Poster Viewing

3:20pm – 5:15pm Theme 2 Cont: Amyloid Clearance, Interstitial Fluid, and the Glymphatic Pathway

Brian Bacskai (3:20pm – 4:00pm) “Vascular Function and Amyloid Clearance”
Oral Abstract Presentations (4:00pm – 5:15pm)
5.15pm – 6.00pm Keynote Address: Jean-Paul Vonsattel

7:00pm – 10.00pm Reception, MIT Museum



September 9, 2016

8:40am – 10:00am Theme 3: Implications of CAA for Clinical Care

Moderator: M. Edip Gurol

Eric Smith (8:40am – 9:20am) “Implications of CAA: Silent MRI Findings and Antithrombotic Treatment”
Magdy Selim (9:20am – 10:00am) “Implications of CAA: Statins and Blood Pressure Treatment”
10:00am – 10:20am Break/Poster Viewing

10:20am – 12:15pm Theme 3 Cont: Implications of CAA for Clinical Care

Charlotte Cordonnier (10:20am – 11:00am) “Implications of CAA: Dementia and Depression”
Oral Abstract Presentations (11:00am – 12:15pm)
12:15pm – 1:40pm Lunch Break/Moderated Poster Presentations



September 9, 2016

1:40pm – 3:00pm Theme 4: CAA, Microvessels, and Microlesions

Moderator: Donna Wilcock

Andy Shih (1:40pm – 2:20pm) “Small but Dangerous: Remote Effects of Cortical Microinfarcts in a Mouse Model”
Susanne van Veluw (3:20pm – 3:00pm) “Microhemorrhage formation in CAA: Post-mortem MRI and In Vivo Microscopy”
3:00pm – 3:20pm Break/Poster Viewing

3:20pm – 5:15pm Theme 4 Cont: CAA, Microvessels, and Microlesions

Mark van Buchem (3:20pm – 4:00pm) “In Vivo Detection of Microlesions”
Oral Abstract Presentations (4:00pm – 5:15pm)


September 10, 2016

8:30am – 9:50am Theme 5: Boston Criteria Turn 20: An International Clinical-Neuroimaging-Neuropathological Validation and Updating

Moderator: Matthew Frosch

Julie Schneider (8:30am – 9:10am) “Grading of CAA Pathology”
Andreas Charidimou (9:10am – 9:50am) “Multicenter Validation of the Boston Criteria”
9:50am – 10:10am Break

10:10am – 11:50am Theme 5 Cont: Boston Criteria Turn 20: An International Clinical-Neuroimaging-Neuropathological Validation and Updating

Oral Abstract, Yusuke Yakushiji (10:10am – 10:25am) “Brain Hemorrhagic lesions in spontaneous intracerebral hemorrhage patients between East and West”
David Werring (10:25am – 11:05am) “Clinical-Neuroimaging-Neuropathological Analysis: Opportunities for Multicenter Studies”
Discussion in preparation for multicenter publication (11:05am – 11:50am)


https://caaforum.org/event/5th-international-caa-conference-2016-boston-ma/

https://clinicaltrials.gov/ct2/show/NCT01821118?term=ponezumab&rank=5